Detecting liver injury in inflammatory bowel disease using transient elastography.

Detecting liver injury by measuring liver stiffness using transient elastography in inflammatory bowel disease patients.

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12611000154909

Enrollment

600

Registered

2011-02-09

Start date

2011-03-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Hepatobiliary disease is a common manifestation of inflammatory bowel disease (IBD). Usually this is apparent by the development of abnormal liver function tests (LFT). In the majority of cases deranged liver tests are transient, can be related to the activity of the inflammatory bowel disease and have no clinical sequalae. However, There are several other causes for deranged LFT’s in IBD which may lead to permanent scarring of the liver. A scarred or fibrotic liver often may not declare itself by abnormal liver tests and transient elastography (TE) is a non invasive method of measuring liver stiffness now used widely in research and clinical practice. In the field of hepatitis C, it is largely replacing the need for a liver biopsy to exclude advance fibrosis and cirrhosis. In this project we seek to find out the prevalence of liver injury in IBD patients by measuring liver stiffness using an operator independent machine called FibroScan (RT).

Interventions

Measuring liver stiffness in kilopascals using transient elastography (FibroScan) in both Crohn's disease and ulcerative colitis patients and comparing them to healthy controls. Each FibroScan measurement will only take 5 minutes for 10 successful acquisitions. This will only be done once. If the patient has an abnormally high reading e.g >8 this will be repeated in 3 months to verify the reading.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

All consecutive consenting patients with a confirmed diagnosis of inflammatory bowel disease. Control patients will be age matched according the following cohorts <25 y.o, 25-35, 35-50 and >50, with no history of liver disease and drink less than 14std drinks per week.

Exclusion criteria

Unconfirmed diagnosis of inflammatory bowel dsiease.

Outcome results